

IACH Preliminary Program

Thursday, 27.09.2018	
	Hall A
13:30-15:30	Pre-congress session: Patients' advocacy groups
14:00-14:20	MDS
14:20-14:40	Rare and orphan diseases
14:40-15:00	Multiple myeloma
15:00-15:20	Stem cell transplantation
15:20-15:30	Discussion
15:30-16:00	Coffee Break
16:00-17:15	Plenary session 1: New frontiers and novel drugs in hematology: from the bench to the bedside
16:00-16:20	Novel anticoagulation agents
16:20-16:40	Check-point inhibitors in lymphoma
16:40-17:00	Advances in CLL therapy
17:00-17:20	Modulation of the microbiome
17:20-17:30	Discussion
17:30-17:45	Break
17:45-19:00	Opening session: Keynote opening lectures and awards
17:45-18:00	<i>Award presentation (H.J. Khoury excellence in research award)</i>
18:00-18:30	Multiple myeloma: past, present and future
18:30-19:00	Advances in the treatment of acute lymphoblastic leukemia
19:15	Welcome Reception

Friday, 28.09.2018			
	Hall A		Hall B
09:15-10:45	Session F1A: Multiple myeloma	09:15-10:45	Session F1B: Allogeneic stem cell transplant indications (1)
09:15-09:35	Diagnosis and management of smoldering myeloma	09:15-09:35	Acute lymphoblastic leukemia
09:35-09:55	Diagnostic and response criteria	09:35-09:55	Acute myeloid leukemia
09:55-10:15	Treatment of non-transplant eligible myeloma	09:55-10:15	Myelodysplastic syndromes
10:15-10:35	Treatment of transplant-eligible myeloma	10:15-10:35	Myeloproliferative neoplasms
10:35-10:45	Discussion	10:35-10:45	Discussion
10:45-11:15	Coffee Break, Poster Viewing and Visit Exhibition		
11:15-12:45	Session F2A: Acute myeloid Leukemia (AML)	11:15-12:45	Session F2B: Allogeneic stem cell transplant indications (2)
11:15-11:35	Risk stratification in AML	11:15-11:35	Hodgkin disease
11:35-11:55	Management of elderly AML	11:35-11:55	B cell lymphomas

11:55-12:15	How to improve on "3+7"?	11:55-12:15	Chronic lymphocytic leukemia
12:15-12:35	Supportive care in AML	12:15-12:35	T cell lymphoma
12:35-12:45	Discussion	12:35-12:45	Discussion
12:45-13:00	Lunch Box Pick-up		
13:00-13:50	Session F3A: IACH lunch debate	13:00-13:50	Session F3B: IACH lunch debate
13:00-13:20	Chemo-free therapy for CLL	13:00-13:20	Chemo-free stem cell mobilization regimens for all
13:30-13:40	Con	13:30-13:40	Con
13:40-13:50	Pro	13:40-13:50	Pro
	Discussion		Discussion
13:50-14:00	Short Break		
14:00-15:30	Session F4A: Non-Hodgkin lymphoma	14:00-15:30	Session F4B: Allogeneic stem cell transplant complications
14:00-14:20	Advances in lymphoma biology	14:00-14:20	Management of endothelium-related complications
14:20-14:40	Therapy of high grade lymphoma	14:20-14:40	Management of viral infections
14:40-15:00	Therapy of HTLV-related lymphoma	14:40-15:00	Management of acute GVHD
15:00-15:20	Therapy of mantle cell lymphoma	15:00-15:20	Prevention and management of long term complications
15:20-15:30	Discussion	15:20-15:30	Discussion
15:30-16:00	Coffee Break, Poster Viewing and Visit Exhibition		
16:00-17:30	Session F5A: Acute lymphoblastic Leukemia (ALL)	16:00-17:30	Session F5B: Advances in allogeneic stem cell transplantation
16:00-16:20	Molecular biology for risk stratification in ALL	16:00-16:20	Choice of donors for haplo-identical transplantation
16:20-16:40	Management of elderly ALL	16:20-16:40	Results of haplo transplants in acute leukemia
16:40-17:00	Intensive therapy for ALL	16:40-17:00	Results of cord blood transplants in children
17:00-17:20	Novel antibodies in relapsed/refractory ALL	17:00-17:20	Novel therapies for chronic GVHD
17:20-17:30	Discussion	17:20-17:30	Discussion
17:30-18:30	Session F6A: Towards personalized and precision medicine	17:30-18:30	Session F6B: Case report forum
17:30-17:50	The art of managing complications	17:30-17:50	How to write a good abstract?
17:50-18:10	Pharmacogenomics in stem cell transplantation	17:50-18:00	Case N°1
18:10-18:30	Biomarkers in hematology: where do we stand?	18:00-18:10	Case N°2
		18:10-18:20	Case N°3
		18:20-18:30	Case N°4

Saturday, 29.09.2018

Hall A		Hall B	
09:15-10:45	Session S1A: Chronic myeloid leukemia (CML) and polycythemia vera	09:15-10:45	Session S1B: Red blood cell disorders
09:15-09:35	Update on polycythemia vera therapy	09:15-09:35	Advances in thalassemia
09:35-09:55	Long term results of 1 st generation TKI	09:35-09:55	Advances in sickle cell disease
09:55-10:15	Role of second generation TKI	09:55-10:15	Red blood cell transfusion in immunized patients
10:15-10:35	Stopping TKIs: for whom, when and how?	10:15-10:35	Allogeneic stem cell transplantation for thalassemia and SCD
10:35-10:45	Discussion	10:35-10:45	Discussion
10:45-11:15	Coffee Break, Poster Viewing and Visit Exhibition		
11:15-12:45	Session S2A: Myelodysplastic syndromes, aplastic anemia and other related disorders	11:15-12:45	Session S2B: Rare diseases and orphan conditions
11:15-11:35	Management of bone marrow failures	11:15-11:35	Systemic mastocytosis
11:35-11:55	Management of low risk MDS	11:35-11:55	Waldenstrom disease
11:55-12:15	Management of PNH	11:55-12:15	Gaucher disease
12:15-12:35	Management of aplastic anemia outside transplant	12:15-12:35	Thrombotic microangiopathy
12:35-12:45	Discussion	12:35-12:45	Discussion
12:45-13:00	Lunch Box Pick-up		
13:00-13:50	Session S3A: IACH lunch debate	13:00-13:50	Session S3B: IACH lunch debate
13:00-13:20	MRD-driven therapy in myeloma Pro	13:00-13:20	Autologous stem cell transplant for systemic amyloidosis Pro
13:30-13:40	Con	13:30-13:40	Con
13:40-13:50	Discussion	13:40-13:50	Discussion
13:50-14:00	Short Break		
14:00-15:30	Session S4A: Clinical experiences from around the world	14:00-16:00	Session S4B: The hematology clinical: making the right diagnosis
14:00-14:15	China	14:00-14:20	Lymphocytosis
14:15-14:30	Argentina	14:20-14:40	Monoclonal component
14:30-14:45	Turkey	14:40-15:00	Hyperferritinemia
14:45-15:00	Japan	15:00-15:20	Molecular techniques for the personalized management of CML
15:00-15:15	India	15:20-15:30	Discussion
15:15-15:30	Hong Kong		
15:30-16:00	Coffee Break, Poster Viewing and Visit Exhibition		
16:00-17:30	Plenary session 2: CAR T cells in hematology		
16:00-16:20	CAR T cells explained to clinicians		
16:20-16:40	Results in acute lymphoblastic leukemia		
16:40-17:00	Results in non-Hodgkin lymphoma and CLL		
17:00-17:20	Allogeneic CAR-T cells		
17:20-17:30	Discussion		
17:30	Meeting conclusions and closure		